An observational study in Cirrhosis, Liver, Acute-On-Chronic Liver Failure and Refractory Ascites, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Active, not recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh — 4 open to participants now, 6 under way, none of them phase 3. Liver Cirrhosis · Post Graduate Institute of Medical Education and Research, Chandigarh.
Among the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 14th registered.
1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →4 of the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh are open now, in 1 country. Recruiting first, the newest first:
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 171 across 526 observational studies indexed under Liver Cirrhosis.
Median enrollment 135 across the 10 interventional studies, 142 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 298 studies on the registry; 44 are open to participants now.
1 of the studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06095466Post Graduate Institute of Medical Education and Research, ChandigarhCirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology | 2027-10-15 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately.
We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) \& cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and Refractory Ascites.
The decrease in systemic vascular resistance (SVR) and redistribution of blood volume with reduced intravascular volume compartment and third space fluid losses. Systemic vasodilatation is compensated by an increase in cardiac output (CO) in the initial stages of compensated cirrhosis. However, as the stage of liver cirrhosis progresses to decompensation, more prominent arterial vasodilatation and reduced SVR leads to a fall in CO. Thus, the cardiac homeostat is reset in a cirrhotic hyperdynamic circulation, wherein an increased heart rate, and therefore, increased cardiac output will no longer be able to compensate for the reduced mean arterial pressure (MAP), and decreased blood volumes in central venous territories.18 Consequent activation of vasoconstrictor systems including renin-angiotensin-aldosterone, vasopressin and the sympathetic nervous system comes into play to maintain the intravascular blood volume and pressure. These compensatory pathways cause an increase in sodium and water retention resulting in refractory ascites and hepatorenal syndrome (HRS). In critically ill patients with cirrhosis, the limited cardiac reserve is further stressed, CCM and heart failure may be diagnosed for the first time when the patient develops sepsis or septic shock.
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis accurately. We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) \& cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) in patients with cirrhosis ACLF and refractory ascites
Definition of CCM is as per updated CCMC criteria of 2020.
Cirrhosis of any etiology, aged between 18-65 years, with Refractory Ascites definition as per International Ascites club.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Echocardiographic assessment
POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin, midodrine, diuretics and domiciliary albumin
Cardiac output measurement by echocardiography after albumin
Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000
Time frame: Day 0
Cardiac output measurement by echocardiography after albumin
Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000
Time frame: Day 1
Cardiac output measurement by echocardiography after albumin
Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000
Time frame: Day 2
Cardiac output measurement by echocardiography after albumin
Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000
Time frame: Day 3
Change in Cystatin C and Neutrophil gelatinase associated lipocalin (NGAL) level
Time frame: day 0
Change in NT Pro brain natriuretic peptide (BNP) level
Time frame: day 0
Change in plasma renin activity level
Time frame: day 0
Change in Galectin-3 level
Time frame: day 0
IVC size and collapsibility changes after 20% albumin
IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
Time frame: Day 0
IVC size and collapsibility changes after 20% albumin
IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
Time frame: Day 2
Lung Ultrasound score change after 20% Albumin
Time frame: Day 1
IVC size and collapsibility changes after 20% albumin
IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.
Time frame: Day 1
Lung Ultrasound score change after 20% Albumin
Time frame: Day 0
Lung Ultrasound score change after 20% Albumin
Time frame: Day 2
Plan to share: Undecided
Ran from Nov 2022 to primary completion in Oct 2026, 47 months.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's 47 months is close to that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Nov 2023 → Oct 2026 and completion Jul 2024 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post Graduate Institute of Medical Education and Research, Chandigarh →